MacFadyen R J, Barr C S, Struthers A D
Department of Clinical Pharmacology, University of Dundee, Ninewells Hospital and Medical School, UK.
Cardiovasc Res. 1997 Jul;35(1):30-4. doi: 10.1016/s0008-6363(97)00091-6.
Experimental data suggest that aldosterone has harmful effects promoting myocardial fibrosis and disturbing autonomic balance. There has been no evidence of these potential effects in intact man.
We report the findings in 31 patients with stable chronic heart failure (CHF) who were treated with spironolactone (50-100 mg/day) or placebo in addition to diuretics and angiotensin converting enzyme (ACE) inhibition. In a controlled randomised double-blind study, we found that spironolactone treatment reduced circulating levels of procollagen type III N-terminal amino peptide, a marker of vascular collagen turnover, and in addition increased time-domain parameters of heart rate variability (n = 24). These latter parameters suggest a parasympathomimetic effect for additional spironolactone. Spironolactone significantly reduced heart rate (prolonged RR interval) particularly during the dawn hours (06.00-09.00 h). In this unbalanced study it was not possible to provide a detailed diurnal assessment of the impact of spironolactone on heart rate variability, but the preliminary data suggest that there may be an interaction with the autonomic nervous system which varies in time.
These are the first human data to show that use of the aldosterone antagonist, spironolactone, can positively improve time-domain heart rate variability and reduce myocardial collagen turnover, as reflected by further reductions in serum procollagen peptide, despite concurrent ACE inhibitor treatment. Residual aldosterone after ACE inhibitor treatment may therefore have a role promoting arrhythmia and cardiac death by two mechanisms. Effects of additional spironolactone on slowing heart rate (and potentially the detrimental effect of aldosterone) were most prominent between 6 a.m. and 10 a.m. when cardiac death is also known to be most prominent.
实验数据表明,醛固酮具有促进心肌纤维化和扰乱自主神经平衡的有害作用。尚无证据表明在健康人体内存在这些潜在影响。
我们报告了31例稳定型慢性心力衰竭(CHF)患者的研究结果,这些患者除接受利尿剂和血管紧张素转换酶(ACE)抑制剂治疗外,还接受了螺内酯(50 - 100毫克/天)或安慰剂治疗。在一项对照随机双盲研究中,我们发现螺内酯治疗可降低III型前胶原N端氨基肽的循环水平,这是血管胶原更新的标志物,此外还增加了心率变异性的时域参数(n = 24)。后一组参数表明额外使用螺内酯具有拟副交感神经作用。螺内酯显著降低心率(延长RR间期),尤其是在黎明时分(06:00 - 09:00)。在这项非均衡研究中,无法对螺内酯对心率变异性的影响进行详细的昼夜评估,但初步数据表明,可能与随时间变化的自主神经系统存在相互作用。
这些是首批人体数据,表明尽管同时使用ACE抑制剂治疗,但使用醛固酮拮抗剂螺内酯可积极改善时域心率变异性并减少心肌胶原更新,血清前胶原肽进一步降低即反映了这一点。因此,ACE抑制剂治疗后残留的醛固酮可能通过两种机制促进心律失常和心脏死亡。额外使用螺内酯对减慢心率(以及醛固酮潜在的有害作用)的影响在上午6点至10点最为显著,而这也是已知心脏死亡最为突出的时段。